Regulatory Affairs & Drug Approval
This unit provides a comprehensive overview of regulatory affairs in the pharmaceutical industry. It covers the history and evolution of drug regulation, the role of regulatory authorities and regulatory affairs departments, the drug development process (non-clinical studies, pharmacology, toxicology), the regulatory pathways for drug approval (IND application, Investigator’s Brochure, NDA), clinical research (phases I-IV, protocols, bioequivalence studies), biostatistics in product development, and data presentation for FDA submissions.
Syllabus & Topics
- 1Regulatory Affairs – Introduction & History: Regulatory Affairs (RA): the discipline within pharmaceutical companies responsible for obtaining marketing authorization, maintaining compliance, and managing regulatory interactions. Historical milestones: (1) 1906 — Pure Food and Drug Act (USA): first federal regulation — prohibited mislabeled/adulterated foods and drugs. (2) 1937 — Sulfanilamide Elixir disaster: diethylene glycol as solvent → 107 deaths → led to 1938 FD&C Act (pre-market approval required). (3) 1962 — Thalidomide disaster (phocomelia birth defects) → Kefauver-Harris Amendment: required proof of EFFICACY + SAFETY before marketing, informed consent required, GMP mandated. (4) 1984 — Hatch-Waxman Act: generic drug approval pathway (ANDA), patent extension. (5) 1992 — PDUFA (Prescription Drug User Fee Act): user fees to speed FDA reviews.
- 2Regulatory Authorities & RA Department: Major regulatory authorities: (1) FDA (USA): CDER (drugs), CBER (biologics), CDRH (devices). (2) EMA (European Medicines Agency): centralized procedure for novel drugs. (3) PMDA (Japan). (4) CDSCO (India). (5) MHRA (UK). (6) TGA (Australia). (7) Health Canada. Role of RA department: (1) Regulatory strategy: determine approval pathway (NDA, ANDA, 505(b)(2), BLA). (2) Compile and submit regulatory dossiers (IND, NDA, ANDA, CTD format). (3) Communicate with regulatory agencies (pre-IND meetings, advisory committee meetings). (4) Manage post-approval changes (supplements, variations). (5) Monitor and ensure compliance with regulations. (6) Track regulatory changes/updates. (7) Label review and approval. Responsibilities of RA professionals: scientific writing, regulatory intelligence, project management, cross-functional coordination.
- 3Drug Development Teams & Non-Clinical Studies: Drug development team: cross-functional — includes medicinal chemistry, pharmacology, toxicology, formulation, analytical, clinical, regulatory, manufacturing, marketing. Non-clinical (preclinical) development: studies conducted BEFORE human testing (IND filing). Pharmacology: (1) Primary pharmacodynamics: mechanism of action, dose-response, efficacy in animal models. (2) Secondary pharmacodynamics: off-target effects. (3) Safety pharmacology: core battery — cardiovascular (hERG assay, telemetry), respiratory (plethysmography), CNS (Irwin test, locomotor activity). Drug metabolism (ADME studies): absorption, distribution, metabolism (CYP enzyme profiling), excretion — in vitro (microsomes, hepatocytes) and in vivo (animal PK studies).
- 4Toxicology Studies: Toxicology — critical for IND application: (1) Single-dose toxicity (acute): determine LD₅₀, dose-response, target organs. In 2 species (rodent + non-rodent). (2) Repeat-dose toxicity (subacute/subchronic/chronic): 14-day, 28-day, 90-day, 6-month, 9-month studies. Determine NOAEL (No Observed Adverse Effect Level). (3) Genotoxicity (mutagenicity): Ames test (bacterial reverse mutation), in vitro chromosome aberration, in vivo micronucleus test. (4) Reproductive toxicity: fertility, embryo-fetal development (teratogenicity), pre/postnatal development. (5) Carcinogenicity: 2-year rodent studies — required for drugs with chronic use. (6) Local tolerance: for parenteral, topical products. (7) Immunotoxicity, phototoxicity: if applicable. NOAEL is used to calculate the starting dose for first-in-human trials: HED (Human Equivalent Dose) = NOAEL × (animal Km / human Km).
- 5IND Application: IND (Investigational New Drug Application): filed with FDA BEFORE initiating clinical trials in humans. Purpose: demonstrate that the drug is reasonably safe for initial testing in humans. Contents: (1) Cover sheet (Form FDA 1571). (2) Table of contents. (3) Introductory statement: drug name, structure, mechanism, therapeutic indication. (4) General investigational plan: Phase I/II/III study design, number of subjects, duration. (5) Investigator’s Brochure (IB). (6) Protocols: detailed clinical study protocols. (7) Chemistry, Manufacturing, and Controls (CMC): drug substance (synthesis, specifications, stability) + drug product (formulation, manufacturing process, specifications, stability). (8) Pharmacology and toxicology data: all preclinical study reports. (9) Previous human experience (if any). FDA review: 30-day safety review. If no clinical hold → study may begin. Clinical hold: FDA can halt the study for safety concerns.
- 6Investigator’s Brochure (IB) & NDA: IB: comprehensive document given to the clinical investigator (physician) summarizing ALL available information about the drug. Contents: (1) Physical/chemical properties. (2) Non-clinical data: pharmacology, PK, toxicology summary. (3) Clinical data: prior human experience, efficacy/safety summary. (4) Dosing information and safety precautions. Updated annually. NDA (New Drug Application): filed AFTER completing clinical trials to request marketing approval. Sections (CTD format — Module 1-5): Module 1: Administrative (regional requirements). Module 2: Summaries (Quality Overall Summary, Non-clinical Overview, Clinical Overview). Module 3: Quality (CMC — drug substance + drug product complete data). Module 4: Non-clinical (all toxicology, pharmacology reports). Module 5: Clinical (all clinical study reports — Phase I/II/III data, integrated summary of safety and efficacy). NDA review: FDA standard review (10 months) or priority review (6 months for significant advance).
- 7Clinical Research & BE Studies: Clinical trial phases: Phase I: first-in-human → safety, tolerability, PK, dose-finding. 20-80 healthy volunteers. Duration: months. Phase II: efficacy + optimal dose. 100-300 patients. Randomized, controlled. Duration: months-2 years. Phase III: confirm efficacy and safety. 1000-5000 patients. Multi-center, randomized, double-blind, controlled. Duration: 1-4 years. Phase IV: post-marketing surveillance → long-term safety, new indications, drug interactions. Bioequivalence (BE) studies: for generic drugs (ANDA) — demonstrate that generic product produces same plasma concentration-time profile as reference product. Design: randomized, crossover, single-dose, fasting study. Parameters: AUC₀₋t, AUC₀₋∞, Cmax. Acceptance: 90% CI for ratio (test/reference) must fall within 80-125%.
- 8Clinical Protocol, Biostatistics & FDA Submissions: Clinical research protocol: (1) Title, objectives, study design. (2) Subject selection (inclusion/exclusion criteria). (3) Treatment plan (dose, route, duration). (4) Assessments and endpoints (primary, secondary). (5) Statistical considerations (sample size, analysis plan). (6) Safety monitoring (adverse event reporting, DSMB). (7) Ethics (informed consent, IRB/IEC approval). (8) Data management. Biostatistics: (1) Study design: parallel, crossover, factorial. (2) Sample size calculation: based on effect size, α (0.05), power (80%). (3) Randomization: simple, stratified, block. (4) Statistical tests: t-test, ANOVA, chi-square, regression. (5) Confidence intervals, p-values, intent-to-treat analysis. FDA data presentation: CTD (Common Technical Document) format — eCTD (electronic). Structured sequence of modules (1-5). ISS (Integrated Summary of Safety) and ISE (Integrated Summary of Efficacy) critical components.
Learning Objectives
Exam Prep Questions
Q1. What is the difference between NDA and ANDA?
NDA (New Drug Application): for NEW/INNOVATOR drugs — requires complete Phase I/II/III clinical trial data proving safety and efficacy. Very expensive ($1-2 billion), takes 10-15 years of development. Filed by innovator companies (Pfizer, Novartis, etc.).
ANDA (Abbreviated New Drug Application): for GENERIC drugs — does NOT require clinical trials for safety/efficacy. Only requires: (1) bioequivalence study (20-40 subjects, single study), (2) same CMC quality data as NDA, (3) paragraph IV certification regarding patents. Much cheaper ($1-5 million), faster (2-3 years). Enabled by Hatch-Waxman Act (1984).
Q2. What is the 80-125% rule in bioequivalence?
The 80-125% rule is the FDA acceptance criterion for bioequivalence: the 90% confidence interval for the ratio of pharmacokinetic parameters (AUC and Cmax) of the test (generic) vs reference (innovator) product must fall ENTIRELY within 80% to 125%. This does NOT mean the generic can be 20% less or 25% more — it’s the CONFIDENCE INTERVAL that must be within this range, meaning the actual point estimate is usually very close to 100% (typically 95-105%). This ensures that the generic truly performs the same as the innovator.
Q3. What is CTD and eCTD?
CTD (Common Technical Document): internationally harmonized format (ICH M4) for regulatory submissions. All major regulatory agencies (FDA, EMA, PMDA, CDSCO) accept CTD format. 5 Modules: M1 (regional/administrative — country-specific), M2 (summaries), M3 (quality/CMC), M4 (non-clinical), M5 (clinical).
eCTD (electronic CTD): the electronic version — mandatory for FDA submissions since 2017. XML-based structure, allows electronic review, lifecycle management (amendments, supplements tracked electronically). Benefits: standardized globally, easier review, better organization.